Identifying antibodies that target systemic amyloid deposition

Amyloid deposition is a worldwide burden associated with a range of largely age-associated diseases. However, the mechanisms underlying the process of amyloid aggregation and possible strategies for degradation are still not fully understood. The aim of this project is to use 6 amyloid-forming proteins (light chain proteins - lambda and kappa, apolipoprotein, transthyretin, lysozyme and fibrinogen) to design antibodies that can bind to different protein forms associated with the aggregation process (monomer, oligomer, fibril). The structural implications of this binding will be fully characterised using a range of structural biology and complementary techniques. This will enhance understanding of the aggregation process and provide opportunity for further development of the antibodies to target the proteins for degradation as a future therapeutic option and to improve quality of life for the ageing population.
The high throughput antibody screening facilities available at UCB enable this project to exploit new ways of working to discover and validate new therapeutic agents and bioactive molecules with increased efficiency and reduced cost. It also bridges academia and industry collaborations promoting innovation and partnerships.